The Potential of Leucomethylene Blue in Methemoglobinemia Treatment: A New Hope for Patients with G6PD? (2025)

Peer-Reviewed Study · Emadi E, Alamdari DH, Sahebkar A · 2025

Emadi E et al., 2025: Review arguing that methylene blue is hazardous in G6PD deficiency, where it can cause haemolysis and death, and proposing leucomethylene blue as a safer alternative.

Since MB is an oxidative agent, its administration in individuals with G6PD deficiency leads to an increased risk of hemolysis through oxidative stress and even death.

Emadi E et al., 2025: Review arguing that methylene blue is hazardous in G6PD deficiency, where it can cause haemolysis and death, and proposing leucomethylene blue as a safer alternative. C3 (harm limb). Study type: narrative review (Curr Med Chem 2025;32:1033-1039); no patients. Authors do not state funders in the record; no CoiStatement. PARTLY SUPPORTS C3: it documents the harm limb the claim asks for (G6PD deficiency, haemolysis, death) but is a mechanistic review, not a case report or series. Proposes leucomethylene blue, not an approved product. Also filed as MTO-28 (claims C3). Study type: review.